Your session is about to expire
What is Visipaque 320
IodixanolThe Generic name of this drug
Treatment SummaryIodixanol is a type of medicine that helps make blood vessels and organs more visible on medical scans. It is often used during coronary angiography, especially in people with kidney problems, since it is believed to be less harmful to the kidneys than other contrast agents.
Visipaqueis the brand name
Visipaque 320 Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Visipaque
Iodixanol
2002
4
Effectiveness
How Visipaque 320 Affects PatientsIodixanol is a special type of dye used during coronary angiography, especially for people with kidney issues. It is considered to be safer for the kidneys than other dyes used during this procedure. Its osmolality (a measure of concentration) is the same as blood.
How Visipaque 320 works in the bodyOrganic iodine compounds absorb x-rays, so that structures containing iodine are more visible on an x-ray image. When injected into the bloodstream, iodixanol will make the inside of the body more visible on an x-ray. This effect lasts until the compound is diluted and eliminated from the body.
When to interrupt dosage
The proposed dosage of Visipaque 320 is contingent upon the determined disorder, including left ventriculography, Arteriography and peripheral arteriography. The amount of dosage is contingent upon the method of administration (e.g. Intravascular or Solution - Intra-arterial; Intravenous), outlined in the table underneath.Condition
Dosage
Administration
peripheral arteriography
, 320.0 mg/mL, 270.0 mg/mL, 652.0 mg/mL, 550.0 mg/mL
, Intra-arterial; Intravenous, Solution, Solution - Intra-arterial; Intravenous, Intravascular, Injection, solution, Injection, solution - Intravascular
angiogram
, 320.0 mg/mL, 270.0 mg/mL, 652.0 mg/mL, 550.0 mg/mL
, Intra-arterial; Intravenous, Solution, Solution - Intra-arterial; Intravenous, Intravascular, Injection, solution, Injection, solution - Intravascular
left ventriculography
, 320.0 mg/mL, 270.0 mg/mL, 652.0 mg/mL, 550.0 mg/mL
, Intra-arterial; Intravenous, Solution, Solution - Intra-arterial; Intravenous, Intravascular, Injection, solution, Injection, solution - Intravascular
peripheral venography
, 320.0 mg/mL, 270.0 mg/mL, 652.0 mg/mL, 550.0 mg/mL
, Intra-arterial; Intravenous, Solution, Solution - Intra-arterial; Intravenous, Intravascular, Injection, solution, Injection, solution - Intravascular
selective coronary arteriography
, 320.0 mg/mL, 270.0 mg/mL, 652.0 mg/mL, 550.0 mg/mL
, Intra-arterial; Intravenous, Solution, Solution - Intra-arterial; Intravenous, Intravascular, Injection, solution, Injection, solution - Intravascular
Arteriography
, 320.0 mg/mL, 270.0 mg/mL, 652.0 mg/mL, 550.0 mg/mL
, Intra-arterial; Intravenous, Solution, Solution - Intra-arterial; Intravenous, Intravascular, Injection, solution, Injection, solution - Intravascular
Contrast Enhanced Computed Tomography (CT) Scanning
, 320.0 mg/mL, 270.0 mg/mL, 652.0 mg/mL, 550.0 mg/mL
, Intra-arterial; Intravenous, Solution, Solution - Intra-arterial; Intravenous, Intravascular, Injection, solution, Injection, solution - Intravascular
Arteriography
, 320.0 mg/mL, 270.0 mg/mL, 652.0 mg/mL, 550.0 mg/mL
, Intra-arterial; Intravenous, Solution, Solution - Intra-arterial; Intravenous, Intravascular, Injection, solution, Injection, solution - Intravascular
excretory urography
, 320.0 mg/mL, 270.0 mg/mL, 652.0 mg/mL, 550.0 mg/mL
, Intra-arterial; Intravenous, Solution, Solution - Intra-arterial; Intravenous, Intravascular, Injection, solution, Injection, solution - Intravascular
Warnings
Visipaque 320 has two contraindications and should not be administered along with the ailments indicated in the following table.Visipaque 320 ContraindicationsCondition
Risk Level
Notes
intrathecal
Do Not Combine
laxative
Do Not Combine
Common Visipaque 320 Drug Interactions
Drug Name
Risk Level
Description
Aclidinium
Minor
Iodixanol may decrease the excretion rate of Aclidinium which could result in a higher serum level.
Acrivastine
Minor
Iodixanol may decrease the excretion rate of Acrivastine which could result in a higher serum level.
Albutrepenonacog alfa
Minor
Iodixanol may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level.
Allylestrenol
Minor
Iodixanol may decrease the excretion rate of Allylestrenol which could result in a higher serum level.
Almasilate
Minor
Iodixanol may decrease the excretion rate of Almasilate which could result in a higher serum level.
Visipaque 320 Toxicity & Overdose RiskIodixanol has been found to be toxic to kidney cells. The effects of this toxicity may include cell death, reduced cellular energy, changes in calcium levels, and alterations in cell structure. These effects are thought to be caused by an increase in oxidative stress.
Visipaque 320 Novel Uses: Which Conditions Have a Clinical Trial Featuring Visipaque 320?
Currently, there are no active clinical trials assessing the potential of Visipaque 320 in Contrast Enhanced Computed Tomography (CT) Scanning, Peripheral Venography and Arteriography.Condition
Clinical Trials
Trial Phases
peripheral venography
0 Actively Recruiting
Contrast Enhanced Computed Tomography (CT) Scanning
0 Actively Recruiting
excretory urography
0 Actively Recruiting
peripheral arteriography
0 Actively Recruiting
left ventriculography
0 Actively Recruiting
angiogram
0 Actively Recruiting
selective coronary arteriography
0 Actively Recruiting
Arteriography
0 Actively Recruiting
Arteriography
0 Actively Recruiting
Visipaque 320 Reviews: What are patients saying about Visipaque 320?
1.3Patient Review
11/17/2007 I had a severe reaction to this medication which included itching in my lower legs for five days. I tried various remedies with no relief. Even now, ten days later, I'm still dealing with hives on other parts of my body.
1.3Patient Review
10/28/2008 Within 20 seconds of the injection, I started feeling weird. My throat and face started swelling up (anaphylactic shock).
1.3Patient Review
11/17/2007 I had a really severe reaction to this treatment. For days afterwards I was intensely itching my legs and nothing provided relief.
1.3Patient Review
10/28/2008 Almost immediately after this was injected into my IV, I started to feel weird. My throat and face started swelling up (anaphylactic shock).
1Patient Review
8/7/2014 I was extremely dizzy, nauseous, and had a severe drop in blood pressure and headache after stents were placed. I also received an absurdly high bill for this treatment - $500 per 100ML dose! After doing some research, I found that most hospitals only pay $1 per ML for this medication. There are much better options out there than this one, especially for people with diabetes or kidney problems.
1Patient Review
8/7/2014 I had to be hospitalized after experiencing severe dizziness, nausea, and a drop in blood pressure following this treatment. I was also very surprised to see that each 100ml dose cost over $500. Iopamidol seems like a much better option, especially for people with diabetes or kidney issues.
Patient Q&A Section about visipaque 320
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.What is the difference between omnipaque and Visipaque?
"There are two types of iodinated contrast agents, Omnipaque and Visipaque, that are used for CT and CTA applications. Omnipaque is typically used for routine CT and low volume CTA studies, while Visipaque is used for high volume CTA and in patients whose EGFR is between 30 and 50ml/min."
Answered by AI
When is Visipaque used?
"Visipaque is a prescription medicine that is used as a contrast agent for CT scans or other radiologic examinations. It may be used alone or with other medications. Visipaque belongs to a class of drugs called iodinated contrast media, which are contrast media that have been treated with iodine."
Answered by AI
How much does Visipaque cost?
"What is the cost for 500 mL of Visipaque injectable solution (320 mg/mL)? The cost for 500 mL of Visipaque injectable solution (320 mg/mL) is around $567, depending on the pharmacy you visit. Prices are for cash paying customers only and are not valid with insurance plans."
Answered by AI
Is Visipaque safer than omnipaque?
"Visipaque had a big win in 2003 when a study in The New England Journal of Medicine found that the iso-osmolar agent was significantly safer than a low-osmolar agent (Omnipaque) in preventing contrast-induced nephropathy in coronary angiography patients."
Answered by AI